Treatment with type-2 selective and non-selective cyclooxygenase inhibitors improves T-cell proliferation in HIV-infected patients on highly active antiretroviral therapy.
Johansson
C Christian
CC
The Biotechnology Centre of Oslo, N-0317 Oslo, Norway.
Bryn
Tone
T
Aandahl
Einar M
EM
Areklett
Maria A
MA
Aukrust
Pål
P
Taskén
Kjetil
K
Frøland
Stig S
SS
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D002455:Cell Division; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D007783:Lactones / Q000627:therapeutic use*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D013450:Sulfones; D013601:T-Lymphocytes / Q000276:immunology*; D019562:Viral Load
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D007213:Indomethacin